CN Patent

CN119255805A — 用于治疗高血压的阿普昔腾坦

Assigned to Actelion Pharmaceuticals Ltd · Expires 2025-01-03 · 1y expired

What this patent protects

本发明涉及化合物阿普昔腾坦，{5‑(4‑溴苯基)‑6[2(5‑溴嘧啶‑2‑基氧基)‑乙氧基]‑嘧啶‑4‑基}‑磺酰胺： 以及其用作内皮素受体拮抗剂在需要治疗的受试者中治疗高血压(包括难治性高血压)的方法中的用途，所述方法包括向该受试者施用包含临床证实有效量的阿普昔腾坦或其药学上可接受的盐的药物组合物。

USPTO Abstract

本发明涉及化合物阿普昔腾坦，{5‑(4‑溴苯基)‑6[2(5‑溴嘧啶‑2‑基氧基)‑乙氧基]‑嘧啶‑4‑基}‑磺酰胺： 以及其用作内皮素受体拮抗剂在需要治疗的受试者中治疗高血压(包括难治性高血压)的方法中的用途，所述方法包括向该受试者施用包含临床证实有效量的阿普昔腾坦或其药学上可接受的盐的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN119255805A
Jurisdiction
CN
Classification
—
Expires
2025-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.